ANIKAnika Therapeutics, Inc.
Anika Therapeutics, Inc. sells orthopedic implants and regenerative solutions for osteoarthritis, targeting early-intervention markets. The next catalyst is Oct 22, 2026 — Q3 2026 Earnings Release, which will test whether recent operational improvements and margin expansion can translate into sustainable revenue growth and profitability.
- Free cash flow has been negative for the last 12 months, with a TTM of -$18.92M.
- Net margin is -7.7% TTM, with revenue down 5.9% YoY.
- The company has a low debt-to-equity ratio of 0.08x, but its path to profitability remains uncertain.
The Read
Anika Therapeutics’ stock has historically reacted modestly to earnings that met expectations but surged about 19% when strong revenue growth, an 8-point gross margin expansion, and early operational improvements boosted profitability.
The schedule
- Thu22Oct
The earnings release tests whether the company can deliver consistent revenue and margin improvements, following a recent earnings miss that failed to meet expectations on product mix.
- Thu29Oct
The earnings release will test the company's ability to meet or exceed expectations on revenue and margin expansion, following a recent miss that highlighted product mix challenges.
- Fri4Dec
The release will test the company's ability to secure favorable reimbursement rates, which directly impacts revenue and cash flow, unlike the last CMS update that had limited impact on the stock.
- Wed17Feb
The earnings release will test the company's ability to deliver consistent revenue and margin improvements, following a recent earnings miss that failed to meet expectations on product mix.
- Thu29Apr
The earnings release will test the company's ability to deliver consistent revenue and margin improvements, following a recent earnings miss that failed to meet expectations on product mix.
- Thu29Jul
Past
- Tue15Sep
Actual outcome: Bull · $21.02 at outcome
The stock closed above the bull target of $19.50, reflecting positive market sentiment following the Investor/Analyst Day. Management's long-term operational targets and updates on the Tactoset commercialization roadmap signaled progress in the regenerative pipeline, reinforcing investor confidence. The price action aligned with the bull case, as the strategic updates outweighed any short-term earnings concerns.
Management will provide long-term operational targets and updates on the regenerative pipeline, specifically focusing on the Tactoset commercialization roadmap.
- Tue21Jul
Actual outcome: Bear · $15.05 at outcome
The stock traded down toward the bear floor following the anticipated launch of a major competitor's rival viscosupplementation product. With no new positive developments to offset competitive concerns ahead of the upcoming Q2 earnings report, the market reacted negatively to the potential threat to Anika's legacy orthopedic revenue streams.
A major competitor is scheduled to launch a rival viscosupplementation product, directly challenging Anika's legacy orthopedic revenue streams.
- Mon1Jun
Actual outcome: Mixed · $14.38 at outcome
Anika did not release a material update regarding the Tactoset commercial rollout, only announcing routine inducement grants of restricted stock units. Without a significant fundamental catalyst or new commercialization data to drive sentiment, the stock experienced a muted reaction, falling slightly by 1.7% and remaining range-bound.
Management update on the commercial rollout and adoption velocity of the Tactoset bone void filler system.
- Thu30Apr
Actual outcome: Bull · $14.85 at outcome
Anika reported Q1 2026 EPS in line with estimates at -$0.37, but delivered strong top-line and margin performance. Total revenue grew 13% driven by Commercial Channel strength, and gross margin expanded by 8 points year-over-year to 64% due to improved operational execution. The market rewarded these early wins from the company's operational transformation and its refocus on core pain management and regenerative products, driving the stock up 19.3%.
Anika reports Q1 results, testing the stock's resilience near 52-week highs amid elevated market expectations for orthobiologics sales.
- Wed11Mar
Actual outcome: Mixed · $14.30 at outcome
Anika Therapeutics reported Q4 earnings that perfectly matched analyst expectations, delivering an EPS of $0.02. Although the stock's immediate reaction was flat, these in-line results provided a stable foundation that allowed shares to steadily climb and eventually surpass the $14.75 bull target in the following months.
Full year results and 2026 guidance issuance.
